autoimmune disease therapy (BEXEL Pharmaceuticals)

N/A

Report date: 2025/03/14 20:00:48

NME

Base Information

Drug Nameautoimmune disease therapy (BEXEL Pharmaceuticals)

Drug Alias Nameimmunosuppressive agent (BEXEL Pharmaceuticals)IL-2 dependent T lymphocyte proliferation modulator (BEXEL Pharmaceuticals)transplant rejection therapy (BEXEL Pharmaceuticals)

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionT lymphocytes inhibitorsImmunosuppressants

TargetsUpdating

Therapy Area/IndicationsRejection of organ transplantationAutoimmune Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesBEXEL Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesBEXEL Pharmaceuticals Inc

Active IndicationsN/A

Inactive IndicationsRejection of organ transplantationAutoimmune Diseases

Other Information

ATC CodeN/A